SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GelTex Pharmaceuticals (GELX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian Jay Patlin who wrote (23)10/7/1997 9:28:00 PM
From: ADEL 7   of 127
 
The stock is markedly over-valued at present time.
FDA approval is almost sure thing.
The issue is that there are many cheap ways to lower serum
phosphorus. RenaGel will have to compete with very cheap drugs
such as CaCO3, Al(OH)3, PhosLo. How much the selling force for
this drug is the issue. I am sure RenaGel has a place but most
likely it will not be the first drug to be used for hyper-
phosphatemia . The issue of hypercalcemia with CaCo3 is no
longer a problem because most of the dialysis units use low
calcium bath for hemodialysis. I am trying to be objective .
It is nice that RenaGel lowers lipids but it will never be
used as a lipid lowering agent. So be carefull with buying the
stock at such value.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News